Although in HER2+ breast cancer cell lines the expression and constitutive phosphorylation of HER3 are frequent, a high variability was observed in this respect in the HER2-amplified cancers of other tissues, and the level of HER3 expression was not a good predictor of its functional significance [83]. This evidence concerns the gene ERBB3 and breast carcinoma.